Biorestorative Therapies reported a quarterly loss of $0.19 per share, beating the Zacks Consensus Estimate for a $0.30 loss by $0.11 per share. The result also improved meaningfully from a $0.56 loss per share a year ago, indicating year-over-year earnings progress. The article is limited to the EPS comparison and does not provide revenue or guidance.
Biorestorative Therapies reported a quarterly loss of $0.19 per share, beating the Zacks Consensus Estimate for a $0.30 loss by $0.11 per share. The result also improved meaningfully from a $0.56 loss per share a year ago, indicating year-over-year earnings progress. The article is limited to the EPS comparison and does not provide revenue or guidance.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
